Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278988838&_hsenc=p2ANqtz-9wQJsP_kS7TZUagIKDcS96H3r9HDDV1SkB98sLrckASWySjvnjzvCkoo7jZHf1ZmTOuWvtogTwTWJ9qt3KGvc6ql9JJQ&utm_content=278988838&utm_source=hs_email